497 related articles for article (PubMed ID: 16740763)
1. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
2. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
3. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ
Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
Simons JW; Sacks N
Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
[TBL] [Abstract][Full Text] [Related]
7. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
[TBL] [Abstract][Full Text] [Related]
10. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
11. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
[TBL] [Abstract][Full Text] [Related]
12. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
[TBL] [Abstract][Full Text] [Related]
15. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R
Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
[TBL] [Abstract][Full Text] [Related]
20. Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens.
Turkeri L; Onol FF; Ozyurek M
Urol Oncol; 2010; 28(3):290-5. PubMed ID: 19362861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
